Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Shields

Showing results (361-370 of 413) with videos related to

Pageof 42
Sort By:
Journal of Clinical Microbiology|June 20, 2020
Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible <i>Citrobacter</i> spp. at a Tertiary Health Care Center over 2 DecadesAhmed Babiker, Daniel R Evans, Marissa P Griffith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 19, 2019
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae InfectionsRyan K Shields, Erin K McCreary, Rachel V Marini, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2023
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patientsEmily L Heil, Kimberly C Claeys, Ellen G Kline, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicityDimitra Mitsani, M Hong Nguyen, Ryan K Shields, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of ResistanceGhady Haidar, Nathan J Philips, Ryan K Shields, et al.
Antimicrobial Agents and Chemotherapy|May 29, 2014
Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agentsReem Almaghrabi, Cornelius J Clancy, Yohei Doi, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 14, 2015
Effects of brain derived neurotrophic factor Val66Met polymorphism in patients with cervical spondylotic myelopathyKingsley O Abode-Iyamah, Kirsten E Stoner, Andrew J Grossbach, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 1, 2014
Targeted versus universal antifungal prophylaxis among liver transplant recipientsG A Eschenauer, E J Kwak, A Humar, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2021
<i>In Vitro</i> Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-TazobactamAbigail M Rubio, Ellen G Kline, Chelsea E Jones, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2013
Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistinCornelius J Clancy, Liang Chen, Jae H Hong, et al.
Pageof 42

Showing results (361-370 of 413) with videos related to

Sort By:
Pageof 42
Journal of Clinical Microbiology|June 20, 2020
Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible <i>Citrobacter</i> spp. at a Tertiary Health Care Center over 2 DecadesAhmed Babiker, Daniel R Evans, Marissa P Griffith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 19, 2019
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae InfectionsRyan K Shields, Erin K McCreary, Rachel V Marini, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2023
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patientsEmily L Heil, Kimberly C Claeys, Ellen G Kline, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicityDimitra Mitsani, M Hong Nguyen, Ryan K Shields, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of ResistanceGhady Haidar, Nathan J Philips, Ryan K Shields, et al.
Antimicrobial Agents and Chemotherapy|May 29, 2014
Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agentsReem Almaghrabi, Cornelius J Clancy, Yohei Doi, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|October 14, 2015
Effects of brain derived neurotrophic factor Val66Met polymorphism in patients with cervical spondylotic myelopathyKingsley O Abode-Iyamah, Kirsten E Stoner, Andrew J Grossbach, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 1, 2014
Targeted versus universal antifungal prophylaxis among liver transplant recipientsG A Eschenauer, E J Kwak, A Humar, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2021
<i>In Vitro</i> Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-TazobactamAbigail M Rubio, Ellen G Kline, Chelsea E Jones, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2013
Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistinCornelius J Clancy, Liang Chen, Jae H Hong, et al.
Pageof 42